Literature DB >> 23636600

Exploration of the medical periodic table: towards new targets.

Nicolas P E Barry1, Peter J Sadler.   

Abstract

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. We discuss recent progress in identifying new target sites and elucidating the mechanisms of action of anti-cancer, anti-bacterial, anti-viral, anti-parasitic, anti-inflammatory, and anti-neurodegenerative agents, as well as in the design of metal-based diagnostic agents. Progress in identifying and defining target sites has been accelerated recently by advances in proteomics, genomics and metal speciation analysis. Examples of metal compounds and chelating agents (enzyme inhibitors) currently in clinical use, clinical trials or preclinical development are highlighted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636600     DOI: 10.1039/c3cc41143e

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  70 in total

1.  Expanding the biological utility of bis-NHC gold(i) complexes through post synthetic carbamate conjugation.

Authors:  Sajal Sen; Yue Li; Vincent Lynch; Kuppuswamy Arumugam; Jonathan L Sessler; Jonathan F Arambula
Journal:  Chem Commun (Camb)       Date:  2019-08-29       Impact factor: 6.222

2.  Systems approach to metal-based pharmacology.

Authors:  Isolda Romero-Canelón; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

3.  Photochemical Properties and Structure-Activity Relationships of RuII Complexes with Pyridylbenzazole Ligands as Promising Anticancer Agents.

Authors:  Dmytro Havrylyuk; David K Heidary; Leona Nease; Sean Parkin; Edith C Glazer
Journal:  Eur J Inorg Chem       Date:  2017-02-15       Impact factor: 2.524

4.  Impact of aromaticity on anticancer activity of polypyridyl ruthenium(II) complexes: synthesis, structure, DNA/protein binding, lipophilicity and anticancer activity.

Authors:  Petar Čanović; Ana Rilak Simović; Snežana Radisavljević; Ioannis Bratsos; Nicola Demitri; Marina Mitrović; Ivanka Zelen; Živadin D Bugarčić
Journal:  J Biol Inorg Chem       Date:  2017-07-10       Impact factor: 3.358

5.  An organometallic inhibitor for the human repair enzyme 7,8-dihydro-8-oxoguanosine triphosphatase.

Authors:  Manuel Streib; Katja Kräling; Kristin Richter; Xiulan Xie; Holger Steuber; Eric Meggers
Journal:  Angew Chem Int Ed Engl       Date:  2013-11-20       Impact factor: 15.336

6.  Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands.

Authors:  Yosra Benabdelouahab; Laura Muñoz-Moreno; Malgorzata Frik; Isabel de la Cueva-Alique; Mohammed Amin El Amrani; María Contel; Ana M Bajo; Tomás Cuenca; Eva Royo
Journal:  Eur J Inorg Chem       Date:  2015-04-09       Impact factor: 2.524

7.  Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.

Authors:  Claire L Soave; Tracey Guerin; Jinbao Liu; Q Ping Dou
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

Review 8.  Carbon monoxide--physiology, detection and controlled release.

Authors:  Stefan H Heinemann; Toshinori Hoshi; Matthias Westerhausen; Alexander Schiller
Journal:  Chem Commun (Camb)       Date:  2014-04-11       Impact factor: 6.222

9.  Classification of Metal-based Drugs According to Their Mechanisms of Action.

Authors:  Eszter Boros; Paul J Dyson; Gilles Gasser
Journal:  Chem       Date:  2019-11-07       Impact factor: 22.804

10.  Rhenium Complexes with Red-Light-Induced Anticancer Activity.

Authors:  Kathrin Wähler; Anja Ludewig; Patrick Szabo; Klaus Harms; Eric Meggers
Journal:  Eur J Inorg Chem       Date:  2014-02-01       Impact factor: 2.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.